Disc Medicine, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Business Address
321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
Mailing Address
321 ARSENAL STREET, SUITE 101, WATERTOWN, MA, 02472
Phone
(617) 674-9274
Fiscal Year End
1231
EIN
851612845
Financial Overview
FY2025
-$76.43M
Net Income
$806.88M
Total Assets
$192.43M
Cash & Equivalents
$-3.42
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
Material Events
8-K
Strategy Change
February 27, 2026
High Impact
- Disc Medicine is re-focusing financial and human resources on other promising drug candidates within its pipeline.
- The company's future strategy will now focus on its other drug candidates, which are expected to drive its value.
8-K
Other
February 17, 2026
High Impact
- Bitopertin was Disc Medicine's lead drug candidate for the rare blood disorder EPP, with estimated peak annual sales potential of $500 million to $1 billion.
- The FDA's Complete Response Letter (CRL) cited no major safety concerns or manufacturing issues, indicating the issues are addressable.
8-K
Other
February 13, 2026
High Impact
- Disc Medicine received a Complete Response Letter (CRL) from the FDA for its lead drug candidate, bitopertin.
- The CRL prevents approval of bitopertin for Erythropoietic Protoporphyria (EPP) in its current form, requiring more information or addressing unresolved concerns.
Insider Trading
STRONG SELL
7 insiders
44 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.